Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini oral session - Gastrointestinal tumours, non-colorectal

LBA10 - Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer: Final results of the NIFE-trial (AIO-YMO HEP-0315), a randomized phase II study of the AIO biliary tract cancer group

Date

17 Sep 2021

Session

Mini oral session - Gastrointestinal tumours, non-colorectal

Presenters

Lukas Perkhofer

Citation

Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741

Authors

L. Perkhofer1, J.K. Striefler2, M. Sinn3, B. Opitz4, T.O. Goetze5, E. Gallmeier6, L. Fischer von Weikersthal7, L. Jacobasch8, D. Waldschmidt9, M. Niedermeier10, M. Sohm11, D. Sookthai12, A. Berger1, A. Beutel1, T. Seufferlein1, T.J. Ettrich1

Author affiliations

  • 1 Department Of Internal Medicine I, University of Ulm, 89081 - Ulm/DE
  • 2 Hematology, Oncology And Tumor Immunology, Charité - Universitätsmedizin Berlin, 10117 - Berlin/DE
  • 3 Department Of Oncology, Hematology And Bmt With Division Of Pneumology, UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, 20246 - Hamburg/DE
  • 4 Medical Oncology, Hospital St. Elisabeth and St. Barbara Halle, Halle/DE
  • 5 Institut Für Klinische Krebsforschung Ikf Gmbh Am Krankenhaus Nordwest, Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest, UCT-University Cancer Center, 60488 - Frankfurt am Main/DE
  • 6 Department Of Gastroenterology And Endocrinology, Philipps University Marburg, Marburg/DE
  • 7 Praxis Dr. L. Fischer Von W., Klinikum St. Marien Amberg, 92224 - Amberg/DE
  • 8 Oncology/heamatology Department, Gemeinschaftspraxis Haematologie - Onkologie, 01307 - Dresden/DE
  • 9 Klinik Für Gastroenterologie Und Hepatologie, Universitätsklinikum Köln (AöR), 50937 - Köln/DE
  • 10 Oncology/heamatology, Private Practice Memmingen, 87700 - Memmingen/DE
  • 11 Sapv, Praxis Dr. Vehling-Kaiser, 84028 - Landshut/DE
  • 12 /, Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest, UCT-University Cancer Center, 60488 - Frankfurt am Main/DE
More

Resources

Login to access the resources on OncologyPRO.

Abstract LBA10

Background

Survival and treatment options in advanced biliary tract cancer (BTC) are limited with the current standard of care gemcitabine/cisplatin. The NIFE study examined nanoliposomal-irinotecan (nal-IRI)/5-FU/leucovorin (LV) as an alternative 1st-line treatment option in advanced BTC.

Methods

NIFE is a prospective, randomized, two-sided, phase II study. Advanced BTC patients were randomized (1:1) to receive either nal-IRI/5-FU/LV (arm A) or gemcitabine/cisplatin (arm B) with a stratification for tumor site (intrahepatic vs. extrahepatic), sex and ECOG (0 vs. 1). Arm A was planned as a Simon’s optimal two-stage design and arm B served as an internal control for selection bias. As primary endpoint a 4 months (mo) progression free survival (PFS) rate ≥50% in the ITT-population was defined.

Results

Between 01/2018-09/2020 93 patients were randomly assigned in 21 German centers. Two patients violating inclusion criteria had to be excluded from the ITT population (n=91) due to inappropriate randomization. The NIFE trial met its primary endpoint with a PFS-rate of 51% at 4mo in the ITT population (arm A). Median PFS in arm A was 5.98mo (2.37-9.59) and in arm B 6.87mo (2.46-7.82). Provisional median overall survival (mOS) was 15.9mo (10.58-21.85) in arm A and 13.63mo (6.51-17.68) in arm B with ongoing follow-up at data closesure. Median PFS in intrahepatic (ICCA) vs. extrahepatic (ECCA) cholangiocarcinoma was 3.45mo (2.10-6.05) vs. 9.59mo (1.94-15.67) in arm A and 7.72mo (6.05-9.46) vs. 1.76mo (0.16-6.87) in arm B. Corresponding mOS times were ICCA 14.19/ECCA 18.23mo in arm A and ICCA 16.36/ECCA 6.34mo in arm B. Table: LBA10

ITT (n=91)
Arm A (n=49) Nal-IRI/5-FU/LV Arm B (n=42) Gemcitabine/cisplatin
PFS rate at 4mo 51.0% ICCA (n=34) 41.2% ECCA (n=15) 73.3% 59.5% ICCA (n=32) 71.9% ECCA (n=10) 20.0%
mPFS 5.98mo (95% CI 2.37-9.59) ICCA (n=34) 3.45mo (95% CI 2.10-6.05) ECCA (n=15) 9.59mo (95% CI 1.94-15.67) 6.87mo (95% CI 2.46-7.82) ICCA (n=32) 7.72mo (95% CI 6.05-9.46) ECCA (n=10) 1.76mo (95% CI 0.16-6.87)
mOS 15.9mo (95% CI 10.58-21.85) ICCA (n=34) 14.19mo (95% CI 7.69-21.85) ECCA (n=15) 18.23mo (95% CI 8.67-30.95) 13.63mo (95% CI 6.51-17.68) ICCA (n=32) 16.36mo (95% CI 7.46-19.91) ECCA (n=10) 6.34mo (95% CI 0.16-NE)
ORR 24.5% 11.9%
DCR at 2mo 57.1% 57.1%

ICCA: intrahepatic CCA, ECCA: Extrahepatic CCA, NE: not estimable

Conclusions

In the phase II NIFE trial nal-IRI/5-FU/LV showed efficacy as 1st-line treatment of advanced BTC with no new safety findings. ECCA and ICCA responded differently to drug interventions, with a clear benefit for nal-IRI/5-FU/LV in ECCA.

Clinical trial identification

AIO-YMO HEP-0315 (NIFE); EudraCT 2016-002467-34; NCT03044587.

Editorial acknowledgement

Legal entity responsible for the study

AIO-Studien GmbH.

Funding

Servier.

Disclosure

M. Sinn: Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: Incyte; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Servier; Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Sanofi. T.O. Goetze: Financial Interests, Personal, Advisory Board: Lilly; Financial Interests, Personal, Advisory Board: MSD Sharp Dohme; Financial Interests, Personal, Advisory Board: Bayer; Financial Interests, Personal, Advisory Board: Celgene; Financial Interests, Personal, Advisory Board: Servier; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Ipsen; Financial Interests, Personal, Invited Speaker: Lilly; Financial Interests, Personal, Invited Speaker: MCI; Financial Interests, Personal, Invited Speaker: MSD Sharp Dohme; Financial Interests, Personal, Research Grant: AstraZeneca; Financial Interests, Personal, Research Grant: Incyte; Financial Interests, Personal, Research Grant: Lilly. D. Waldschmidt: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Bayer; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: Celgene; Financial Interests, Personal, Advisory Board: Eisai; Financial Interests, Personal, Advisory Board: Incyte; Financial Interests, Personal, Advisory Board: Ipsen; Financial Interests, Personal, Advisory Board: Falk; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Servier; Financial Interests, Personal, Advisory Board: Shire Baxalta; Financial Interests, Personal, Advisory Board: Sirtex. T. Seufferlein: Financial Interests, Personal, Advisory Board: Sanofi; Financial Interests, Personal, Advisory Board: Pierre Fabre; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Baxalta; Financial Interests, Personal, Advisory Board: Servier; Financial Interests, Personal, Speaker’s Bureau: Sanofi; Financial Interests, Personal, Speaker’s Bureau: Pierre Fabre; Financial Interests, Personal, Speaker’s Bureau: Pfizer; Financial Interests, Personal, Speaker’s Bureau: Baxalta; Financial Interests, Personal, Speaker’s Bureau: Servier; Financial Interests, Personal, Research Grant: Boehringer; Financial Interests, Personal, Research Grant: Sanofi; Financial Interests, Personal, Research Grant: Celgene; Financial Interests, Personal, Research Grant: Amgen. T.J. Ettrich: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Bayer; Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Advisory Board: Merck; Financial Interests, Personal, Advisory Board: Ipsen; Financial Interests, Personal, Invited Speaker: Ipsen; Financial Interests, Personal, Advisory Board: Sanofi Aventis; Financial Interests, Personal, Invited Speaker: Eisai; Financial Interests, Personal, Advisory Board: Pierre-Fabre Pharma; Financial Interests, Personal, Advisory Board: Incyte; Financial Interests, Personal, Advisory Board: Lilly; Financial Interests, Personal, Advisory Board: Bristol Myers Squibb; Financial Interests, Institutional, Research Grant: Servier; Financial Interests, Institutional, Research Grant: Sanofi Aventis; Financial Interests, Institutional, Research Grant: Celgene. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.